Research graph
References from Single-item measures of perceived side effect burden for people with cancer: A systematic scoping review. Local targets link to admitted publications; unresolved targets remain external evidence.
Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review
10.1093/jnci/djr541 · 2012 · External reference
Quality of life among long-term (⩾5years) colorectal cancer survivors – Systematic review.
10.1016/j.ejca.2010.06.010 · 2010 · External reference
Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy
10.1002/cncr.31133 · 2018 · External reference
Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients
2022 · External reference
How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
2022 · External reference
The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments
10.1007/s11136-024-03740-x · 2024 · External reference
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial
10.1200/jco.23.00377 · 2024 · External reference
Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
10.1093/jnci/djp386 · 2009 · External reference
Impact of oxaliplatin-induced neuropathy: a patient perspective
2012 · External reference
Symptom experience of patients undergoing treatment for multiple myeloma: a longitudinal real-world electronic patient-reported outcomes study
2024 · External reference
Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA
2023 · External reference
The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review
2016 · External reference
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial
10.1016/s1470-2045(25)00679-5 · 2026 · External reference
An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology
10.1186/s41687-022-00478-3 · 2022 · External reference
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
10.1158/1078-0432.ccr-15-2035 · 2016 · External reference
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop
10.1016/j.jval.2017.09.009 · 2018 · External reference
Broadening the definition of tolerability in cancer clinical trials to capture the patient experience
2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure
10.1200/jco.1993.11.3.570 · 1993 · External reference
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer
1999 · External reference
Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder
10.1038/bjc.2016.284 · 2016 · External reference
Unresolved reference
External reference
Telling more than we can know: Verbal reports on mental processes
10.1037/0033-295x.84.3.231 · 1977 · External reference
Updated methodological guidance for the conduct of scoping reviews
10.11124/jbies-20-00167 · 2020 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Single-Item Measures of Side-Effect
2025 · External reference
Beyond PICO: the SPIDER tool for qualitative evidence synthesis
10.1177/1049732312452938 · 2012 · External reference
Unresolved reference
External reference
Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21
10.1038/sj.bjc.6606086 · 2011 · External reference
Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale
10.1002/cam4.385 · 2015 · External reference
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
10.1093/oncolo/oyad028 · 2023 · External reference
Comparability of interview- and self-administration of the Functional Assessment of Cancer Therapy-General (FACT-G) in English- and Spanish-speaking ambulatory cancer patients
10.1097/mlr.0b013e3181648e6e · 2008 · External reference
Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer
2024 · External reference
Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium
10.1016/j.ijrobp.2021.11.024 · 2022 · External reference
The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma
10.3109/10428194.2012.711830 · 2013 · External reference
Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16)
10.1186/s41687-024-00776-y · 2024 · External reference
Comparison of Simple-Summated Scoring and Toxicity Index Scoring of Symptom Bother in the NSABP B-30 Clinical Trial
10.1007/s11482-022-10103-6 · 2023 · External reference
Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302)
10.1002/cam4.3506 · 2020 · External reference
Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancer
10.1002/cncr.35025 · 2024 · External reference
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma
10.1001/jamanetworkopen.2024.3854 · 2024 · External reference
Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04
10.1007/s11136-024-03746-5 · 2024 · External reference
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer
10.1186/s41687-024-00823-8 · 2024 · External reference
Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma
10.1016/j.jval.2018.04.1371 · 2018 · External reference
Exploration of baseline patient-reported side effect bother from cancer therapy
10.1177/1740774520910389 · 2020 · External reference
Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials
10.1007/s11136-023-03426-w · 2023 · External reference
Comparative Analysis of Paper-Based and Web-Based Versions of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) Questionnaire in Breast Cancer Patients: Randomized Crossover Study
10.2196/18269 · 2021 · External reference
An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study
10.2196/10004 · 2019 · External reference
Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18)
10.1016/j.ygyno.2014.12.002 · 2015 · External reference
10.1186/s12955-019-1162-5
10.1186/s12955-019-1162-5 · 2019 · External reference
Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5
10.1016/j.jgo.2025.102304 · 2025 · External reference
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
2014 · External reference
Unresolved reference
External reference
Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials
10.1093/annonc/mdx043 · 2017 · External reference
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
10.1016/s1053-4296(03)00031-6 · 2003 · External reference
